Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

1(33.3%)

N/A

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06054269Phase 3Active Not Recruiting

Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP

Role: collaborator

NCT05522296Completed

Break-through Infection Following Mpox vaccinatIon

Role: collaborator

NCT04526821Phase 2Terminated

Lactoferrin for Prevention of COVID-19 in Health Care Workers

Role: collaborator

NCT02355223Not ApplicableUnknown

Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission

Role: collaborator

All 4 trials loaded